Takeda zapped for destroying Actos records; India balks at undermining BMS Sprycel patent; Zoetis to buy back $500M in shares;

@FiercePharma: Actavis' merger cost-cutting isn't Valeant-style. But it's still $1.8B. Story | Follow @FiercePharma

@CarlyHFierce: Valeant and Allergan's wining-and-dining shows docs still hold the script reins. More | Follow @CarlyHFierce

> A state court jury in West Virginia ordered Takeda to pay $155,000 in penalties for destroying files about the development and marketing of its diabetes drug Actos, which was said to prevent a defendant from proving a case about the effects of the drug. Story

> India's Trade Ministry is said to be reluctant to issue a compulsory license to allow a generic of Bristol-Myers Squibb's ($BMY) Sprycel even though the Health Ministry is urging it. Story (sub. req.)

> Animal health leader Zoetis ($ZTS), which is fighting off Bill Ackman's hedge fund from pushing it to sell the company, has approved a $500 million share buy-back. Release

> Bayer's Eylea has been granted another approval in Japan, this one to treat diabetes-related visual impairment (DME). Report

Medical Device News

@FierceMedDev: FDA panel recommends approval of Alcon intraocular lens. More | Follow @FierceMedDev

@EmilyWFierce: Sales of heart devices pump new life into $MDT's Q2 earnings, boost revenues to $4.37B. Story | Follow @EmilyWFierce

> Brain tumor treatment device gets early trial halt for efficacy as a combo with chemo. More

> Texas judge tosses out 76 suits in J&J's ongoing vaginal mesh litigation. Story

> FDA to more than double staff in China as visa issues appear resolved. Article

Biotech News

@FierceBiotech: Novartis joins Atlas in launching a CRISPR Cas biotech with a $15M bankroll. Article | Follow @FierceBiotech

@JohnCFierce: FDA orders $CYTR to halt patient enrollment after death of a cancer patient - and they're scrambling to lift hold. Story | Follow @JohnCFierce

@DamianFierce: $ACT's Saunders: looking at a "mid to high teens cut to our R&D spend" after $AGN integration, mostly "low-value programs." | Follow @DamianFierce

> Novartis revs up a promising pharmacoeconomic case for heart failure drug LCZ696. Report

> AstraZeneca toasts to independent living with big plans for its Pfizer-free future. Story

> FDA orders CytRx to halt patient enrollment after death of a cancer patient. Article

Biotech Research News

> Microbiome research project IDs 'good' bacteria that combat obesity. Article

> Knocking out a pair of genes may help prevent a relapse of leukemia. Story

> Structural modeling at Scripps points to better Ebola drug cocktails. Article

> Cardiovascular investigator pinpoints a new drug target in heart disease. Item

> Brown fat fingers a new target for metabolic disorders, including diabetes. More

Pharma Manufacturing News

> Ranbaxy fights FDA for killing its approval to make generic Nexium. Story

> Apotex recalling blood pressure med made at banned plant in India. Report

> Recipharm picks up two more plants, this time in Portugal. Item

> Bristol-Myers to build $900M biologics plant in Ireland. Story

> Getting more FDA inspectors in China on Hamburg's agenda for trip to China. Article

And Finally... A new study found that employees at a company moved to a consumer directed health plan with high deductibles filled fewer prescriptions of both branded and generic meds. Story


Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.